Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are among the most frequent indications for allogeneic hematopoietic cell transplantation (alloHCT). AlloHCT represents the only option with curative potential for many patients and is standard of care for fit patients with high-risk disease features. Survival 3 years after alloHCT is between 50 to 60% for patients with AML in remission, around 30% for patients with relapsed/refractory AML, and between 45 to 55% for patients with MDS1.

Source: Biology of Blood and Marrow Transplantation - May 22, 2021 Category: Hematology Authors: Corrado Zuanelli Brambilla, Stephanie M. Lobaugh, Josel D. Ruiz, Parastoo B. Dahi, Aaron D. Goldberg, James W. Young, Boglarka Gyurkocza, Brian C. Shaffer, Doris M. Ponce, Roni Tamari, Miriam Sanchez Escamilla, Nerea Castillo Flores, Ioannis Politikos, Mi Source Type: research